Akebia Therapeutics Statistics
Total Valuation
AKBA has a market cap or net worth of $280.56 million. The enterprise value is $281.26 million.
| Market Cap | 280.56M |
| Enterprise Value | 281.26M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, before market open.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AKBA has 209.37 million shares outstanding. The number of shares has increased by 2.56% in one year.
| Shares Outstanding | 209.37M |
| Shares Change (YoY) | +2.56% |
| Shares Change (QoQ) | +0.86% |
| Owned by Insiders (%) | 2.47% |
| Owned by Institutions (%) | 26.68% |
| Float | 189.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.44 |
| Forward PS | 1.45 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18
| Current Ratio | 1.18 |
| Quick Ratio | 0.82 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.61 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -20.60% |
| Return on Capital (ROIC) | -329.75% |
| Revenue Per Employee | $1.17M |
| Profits Per Employee | -$310,928 |
| Employee Count | 167 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 3.98 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +68.98% in the last 52 weeks. The beta is 0.84, so AKBA's price volatility has been lower than the market average.
| Beta (1Y) | 0.84 |
| 52-Week Price Change | +68.98% |
| 50-Day Moving Average | 1.57 |
| 200-Day Moving Average | 1.32 |
| Relative Strength Index (RSI) | 37.79 |
| Average Volume (30 Days) | 4,875,041 |
Short Selling Information
The latest short interest is 13.69 million, so 6.54% of the outstanding shares have been sold short.
| Short Interest | 13.69M |
| Short Previous Month | 13.40M |
| Short % of Shares Out | 6.54% |
| Short % of Float | 7.24% |
| Short Ratio (days to cover) | 1.42 |
Income Statement
In the last 12 months, AKBA had revenue of $194.62 million and -$51.93 million in losses. Loss per share was -$0.28.
| Revenue | 194.62M |
| Gross Profit | 120.47M |
| Operating Income | -43.02M |
| Pretax Income | -51.93M |
| Net Income | -51.93M |
| EBITDA | -4.05M |
| EBIT | -45.89M |
| Loss Per Share | -$0.28 |
Balance Sheet
The company has $42.93 million in cash and $43.63 million in debt, giving a net cash position of -$705,000 or -$0.00 per share.
| Cash & Cash Equivalents | 42.93M |
| Total Debt | 43.63M |
| Net Cash | -705,000 |
| Net Cash Per Share | -$0.00 |
| Equity / Book Value | -30.58M |
| Book Value Per Share | -0.15 |
| Working Capital | 18.28M |
Cash Flow
| Operating Cash Flow | -23.38M |
| Capital Expenditures | n/a |
| Free Cash Flow | -23.38M |
| FCF Per Share | -$0.13 |
Margins
Gross margin is 61.90%, with operating and profit margins of -22.10% and -26.68%.
| Gross Margin | 61.90% |
| Operating Margin | -22.10% |
| Pretax Margin | -26.68% |
| Profit Margin | -26.68% |
| EBITDA Margin | -2.08% |
| EBIT Margin | -23.58% |
| FCF Margin | -12.02% |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.56% |
| Shareholder Yield | -2.56% |
| Earnings Yield | -18.51% |
| FCF Yield | -8.33% |
Analyst Forecast
The average price target for AKBA is $4.67, which is 248.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.67 |
| Price Target Difference | 248.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 17.82% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AKBA has an Altman Z-Score of -8.43 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.43 |
| Piotroski F-Score | 3 |